Biocytogen: 9-month revenue up 49%, attributable net profit up 174%
Beijing-based Biocytogen Pharmaceuticals reported nine-month revenue up 49.09% and attributable net profit up 173.77%, according to a TradingView summary.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Biocytogen Pharmaceuticals of Beijing posted a 49.09% rise in revenue for the first nine months. Attributable net profit climbed 173.77%, and adjusted net profit rose 307.62%.
The company credited growth mainly to its pharmacology and efficacy testing services and its animal models business. At the same time, spending on research and development and net cash outflows from investing activities increased.
why it matters
Figures like these matter mainly to the company's shareholders and to investors following Chinese biotech stocks. Profit growing much faster than revenue points to operating leverage, though the source does not break down the drivers further. Higher R&D and investing outflows show the company is still spending heavily on expansion.
tags
instruments
sources
- Biocytogen Pharmaceuticals Beijing: 9M revenue rose 49.09%, while attributable net profit increased 173.77% — TradingView, 29 October 2026 at 08:53 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗